Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezagepras vs Sodium Phenylbutyrate PK/Safety in Healthy Subjects
NCT05349435Phase 1Terminated
- Sponsor
- Liminal BioSciences Inc.
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fezagepras in hyperammonemia (2 cohorts), sponsored by Liminal BioSciences Inc. Primary endpoint: Safety and tolerability. Started May 2022; status: terminated.
02
Drugs
fezagepras
03
Conditions
hyperammonemia
Beyond the preview
Go deeper on NCT05349435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349435.